Neosporosis

Neosporosis is a protozoal infectious disease caused by the obligate intracellular apicomplexan parasite Neospora caninum. It primarily affects dogs, particularly puppies, where it causes progressive neuromuscular disease characterized by ascending paralysis, muscle atrophy, and contracture. The disease can also cause abortion and neonatal mortality in cattle, but in dogs, it is a significant cause of polyradiculoneuritis and myositis. The parasite has a heteroxenous life cycle with canids (dogs, wolves, dingoes) as definitive hosts and cattle, sheep, goats, and other herbivores as intermediate hosts. In dogs, infection can be acquired transplacentally (vertical transmission) or by ingestion of tissue cysts from infected intermediate hosts. Clinical neosporosis is most commonly seen in congenitally infected puppies, but adult dogs with immunosuppression may also develop clinical disease. The disease is characterized by a wide spectrum of clinical signs, ranging from subclinical infection to severe, fatal neuromuscular disease.

The causative agent is Neospora caninum, an obligate intracellular protozoan parasite belonging to the phylum Apicomplexa, family Sarcocystidae. The parasite exists in three infectious stages: tachyzoites, bradyzoites (in tissue cysts), and sporozoites (in oocysts). Tachyzoites are rapidly dividing stages that cause active infection and tissue damage, while bradyzoites are slow-dividing stages that persist in tissue cysts, particularly in neural and muscular tissues. The definitive hosts are canids, primarily domestic dogs, which shed unsporulated oocysts in feces after ingesting tissue cysts from infected intermediate hosts. Oocysts sporulate in the environment within 24-48 hours and become infective. Intermediate hosts, such as cattle, become infected by ingesting sporulated oocysts. In dogs, infection occurs through ingestion of tissue cysts (from raw meat or infected prey) or transplacentally from an infected dam to her puppies. The parasite can also be transmitted via ingestion of oocysts from the environment, but this is less common in dogs. The virulence of N. caninum strains varies, with some strains being more pathogenic than others. The parasite has a tropism for neural and muscular tissues, leading to the characteristic clinical signs.

Neosporosis is a worldwide zoonotic-like disease (though not zoonotic to humans) with a global distribution. It is a major cause of abortion in cattle, leading to significant economic losses in the livestock industry. In dogs, the prevalence of N. caninum infection varies geographically, with seroprevalence rates ranging from 0.5% to 30% depending on the region and dog population. Dogs of all breeds and ages can be infected, but clinical disease is most commonly seen in puppies, particularly those under 6 months of age. Congenital transmission is the most common route of infection in puppies, and it can occur in successive litters from the same dam. Certain breeds, such as Boxers, Greyhounds, and Labrador Retrievers, may have a higher incidence, but this may reflect reporting bias. Adult dogs with immunosuppression (e.g., due to concurrent infections, chemotherapy, or corticosteroid therapy) are at increased risk of developing clinical disease. The disease is more prevalent in rural areas where dogs have access to raw meat, cattle placentas, or aborted fetuses. There is no sex predilection. The disease is not directly contagious between dogs, except for transplacental transmission from dam to offspring.

The pathophysiology of neosporosis involves the invasion and destruction of host cells by tachyzoites, leading to inflammation and tissue necrosis. After ingestion of tissue cysts or oocysts, the parasite excysts in the small intestine and releases bradyzoites or sporozoites, which then invade the intestinal epithelium and differentiate into tachyzoites. Tachyzoites disseminate via the bloodstream and lymphatics to various tissues, with a predilection for the central nervous system (CNS), peripheral nerves, and skeletal muscle. In the CNS, tachyzoites infect neurons, glial cells, and macrophages, causing focal necrosis, non-suppurative inflammation, and the formation of granulomas. In the peripheral nervous system, the parasite causes polyradiculoneuritis, characterized by inflammation and demyelination of nerve roots and peripheral nerves. In skeletal muscle, tachyzoites cause myositis with myofiber necrosis and regeneration. The immune response, particularly cell-mediated immunity, is crucial in controlling the infection. However, the inflammatory response can also contribute to tissue damage. In puppies, the immature immune system may be unable to control the rapid multiplication of tachyzoites, leading to severe, progressive disease. The parasite can also form tissue cysts containing bradyzoites, which persist for the life of the host and can reactivate if the host becomes immunosuppressed. The hallmark lesion is a non-suppurative meningoencephalomyelitis with multifocal necrosis and intralesional protozoal organisms.

Predisposing factors for clinical neosporosis in dogs include: 1) Age: Puppies, especially those under 6 months, are most susceptible due to an immature immune system and the high rate of congenital transmission. 2) Immunosuppression: Adult dogs receiving immunosuppressive drugs (e.g., corticosteroids, cyclosporine) or with concurrent infections (e.g., canine distemper, ehrlichiosis) are at increased risk of reactivation of latent infection. 3) Breed: Certain breeds may have a genetic predisposition, though this is not well-defined. 4) Nutritional status: Malnutrition may impair immune function. 5) Management factors: Dogs with access to raw meat, cattle placentas, or aborted fetuses have a higher risk of infection. 6) Congenital transmission: Puppies born to infected dams are at high risk, and the risk increases with successive pregnancies. 7) Stress: Physical or environmental stress may trigger clinical disease in subclinically infected dogs.

Clinical signs of neosporosis in dogs vary depending on the age of the dog and the severity of infection. In puppies, the disease typically presents as a progressive, ascending paralysis that begins with pelvic limb weakness and ataxia. The paralysis progresses to spastic paresis and eventually flaccid paralysis. Muscle atrophy, particularly of the pelvic limbs, is prominent. Contracture of the gastrocnemius muscle leads to a characteristic 'knuckling' of the hind paws and a stiff, stilted gait. Other signs include dysphagia, dysphonia, megaesophagus (due to esophageal muscle involvement), and respiratory distress (due to diaphragmatic and intercostal muscle paralysis). In adult dogs, clinical signs may be more variable and can include myositis (muscle pain, stiffness, elevated creatine kinase), neurological deficits (seizures, tremors, ataxia, cranial nerve deficits), and systemic signs such as fever, lethargy, and anorexia. Some dogs may develop myocarditis, leading to cardiac arrhythmias and heart failure. Ocular signs, such as uveitis and retinitis, have also been reported. The disease can be rapidly progressive and fatal if not treated early.

Differential diagnoses for neosporosis in dogs include: 1) Canine distemper virus infection: Causes similar neurological signs, but also respiratory and gastrointestinal signs, and intracytoplasmic inclusion bodies in various tissues. 2) Toxoplasmosis (Toxoplasma gondii): Causes similar neuromuscular signs, but is more common in cats; can be differentiated by serology and PCR. 3) Polyradiculoneuritis (coonhound paralysis): Acute, ascending flaccid paralysis without muscle atrophy or contracture; often associated with raccoon bites. 4) Myasthenia gravis: Causes generalized weakness, megaesophagus, and exercise intolerance; diagnosed by acetylcholine receptor antibody titers. 5) Muscular dystrophy: Inherited myopathy with muscle weakness and atrophy; diagnosed by muscle biopsy and genetic testing. 6) Intervertebral disc disease: Causes acute paralysis, but usually with spinal pain and no muscle atrophy; diagnosed by imaging. 7) Tick paralysis: Acute ascending flaccid paralysis due to neurotoxin; resolves after tick removal. 8) Botulism: Acute flaccid paralysis due to toxin ingestion; diagnosed by toxin detection in serum or feces. 9) Polymyositis: Immune-mediated muscle inflammation; diagnosed by muscle biopsy and response to immunosuppressive therapy. 10) Spinal cord trauma: Acute paralysis with a history of trauma; diagnosed by imaging.

The diagnostic algorithm for neosporosis in dogs involves: 1) Clinical suspicion: Consider neosporosis in puppies with progressive ascending paralysis, muscle atrophy, and contracture, especially if there is a history of exposure to raw meat or cattle. 2) Hematology and serum biochemistry: May show elevated creatine kinase (CK) and aspartate aminotransferase (AST) due to muscle damage. 3) Serology: Detection of antibodies against N. caninum using indirect fluorescent antibody test (IFAT) or enzyme-linked immunosorbent assay (ELISA). A positive IgM titer suggests recent infection, while a positive IgG titer indicates exposure. High titers (≥1:800) are supportive of clinical disease. 4) Molecular testing: Polymerase chain reaction (PCR) on blood, cerebrospinal fluid (CSF), or tissue samples can detect parasite DNA and confirm the diagnosis. 5) CSF analysis: May show elevated protein and mononuclear pleocytosis. 6) Electromyography (EMG): May reveal denervation potentials and myopathic changes. 7) Muscle biopsy: Histopathology may show myositis with intralesional tachyzoites or tissue cysts. 8) Imaging: MRI of the spinal cord may show hyperintense lesions in the white matter. 9) Response to treatment: Clinical improvement after initiation of antiprotozoal therapy supports the diagnosis.

Hematology: Complete blood count (CBC) may be normal or show mild anemia, leukocytosis, or eosinophilia. Serum Biochemistry: Elevated creatine kinase (CK) and aspartate aminotransferase (AST) are common due to muscle damage. Alkaline phosphatase (ALP) may be elevated due to corticosteroid therapy or liver involvement. Globulins may be increased due to chronic inflammation. Urinalysis: Usually unremarkable. Blood Gas Analysis: May show respiratory acidosis if respiratory muscles are affected. Specific Biomarkers: Cardiac troponin I may be elevated if myocarditis is present. Serology: Detection of anti-N. caninum antibodies (IgG and IgM) by IFAT or ELISA. A four-fold rise in IgG titers over 2-4 weeks is suggestive of active infection. PCR: Detection of N. caninum DNA in blood, CSF, or tissue samples is highly specific. CSF Analysis: Elevated protein (50-200 mg/dL) and mononuclear pleocytosis (10-100 cells/µL). Electromyography: May show fibrillation potentials and positive sharp waves in affected muscles.

Radiography: Thoracic radiographs may reveal megaesophagus (dilated esophagus) due to esophageal muscle dysfunction. Aspiration pneumonia may be seen as alveolar infiltrates. Ultrasonography: Abdominal ultrasound may be unremarkable, but can help rule out other causes of paralysis. Computed Tomography (CT): CT of the spine may be normal or show mild changes. Magnetic Resonance Imaging (MRI): MRI of the spinal cord may show multifocal hyperintense lesions on T2-weighted images, particularly in the white matter, due to inflammation and necrosis. MRI of the brain may show similar lesions in cases with CNS involvement. Echocardiography: If myocarditis is suspected, echocardiography may show decreased myocardial contractility and arrhythmias.

Fine Needle Aspirate (FNA): FNA of affected muscles may show mixed inflammatory cells (lymphocytes, macrophages, plasma cells) and occasionally tachyzoites. CSF cytology: May show mononuclear pleocytosis with occasional organisms. Histopathology: Muscle biopsy reveals multifocal myofiber necrosis, phagocytosis, and non-suppurative inflammation (lymphocytes, macrophages, plasma cells). Intralesional tachyzoites may be seen in acute cases, and tissue cysts (containing bradyzoites) may be seen in chronic cases. Immunohistochemistry (IHC) using anti-N. caninum antibodies can confirm the presence of the parasite. In the spinal cord and nerve roots, histopathology shows non-suppurative meningoencephalomyelitis, polyradiculoneuritis, and demyelination. Special stains such as Giemsa or hematoxylin and eosin (H&E) can highlight the organisms.

The primary treatment for neosporosis in dogs involves antiprotozoal therapy. The recommended protocol is a combination of clindamycin (10-20 mg/kg PO q8h) and pyrimethamine (1 mg/kg PO q24h) for at least 4 weeks. Alternatively, trimethoprim-sulfadiazine (15-30 mg/kg PO q12h) can be used in combination with pyrimethamine. In severe cases, treatment may need to be extended for 8-12 weeks. Supportive care includes: 1) Fluid therapy to maintain hydration and electrolyte balance. 2) Nutritional support, including feeding tubes if megaesophagus or dysphagia is present. 3) Physical therapy to prevent muscle contractures and maintain joint mobility. 4) Management of aspiration pneumonia with antibiotics if indicated. 5) Corticosteroids (e.g., prednisone 0.5-1 mg/kg PO q12h) may be used to reduce inflammation, but should be used cautiously as they may exacerbate the infection. 6) In cases of megaesophagus, elevate the food bowl and feed small, frequent meals. 7) Monitor for adverse effects of antiprotozoal drugs, such as bone marrow suppression (pyrimethamine) and gastrointestinal upset (clindamycin).

The prognosis for neosporosis in dogs is guarded to poor, especially in puppies with severe, progressive disease. Early diagnosis and prompt treatment can improve the outcome, but many puppies die or are euthanized due to irreversible neurological damage. Puppies that survive may have permanent muscle atrophy, contractures, and neurological deficits. Adult dogs with mild clinical signs may recover with treatment, but relapse can occur if the dog becomes immunosuppressed. The prognosis is worse if there is severe muscle atrophy, megaesophagus, or respiratory involvement. Negative prognostic indicators include: 1) Rapid progression of paralysis. 2) Severe muscle atrophy. 3) Presence of megaesophagus. 4) Lack of response to treatment within 2 weeks. 5) High CSF protein concentration. The mortality rate in clinically affected puppies is high, with some studies reporting up to 50% mortality despite treatment.

Follow-up care for dogs with neosporosis includes: 1) Recheck examinations every 2-4 weeks during treatment to monitor clinical response and adverse effects. 2) Serial serum CK levels to assess muscle damage; levels should decrease with successful treatment. 3) Repeat serology (IgG titers) every 3-6 months to monitor antibody levels; a decreasing titer suggests resolution of infection. 4) If the dog has megaesophagus, repeat thoracic radiographs every 4-6 weeks to assess esophageal dilation and check for aspiration pneumonia. 5) Physical therapy should be continued for several months to improve muscle strength and prevent contractures. 6) In breeding dogs, it is recommended to not breed infected dogs, as congenital transmission can occur. 7) Long-term monitoring for relapse, especially if the dog receives immunosuppressive therapy for other conditions. 8) Provide nutritional counseling to maintain body condition.

Pearls: 1) Neosporosis should be a top differential in any young puppy with progressive ascending paralysis and muscle atrophy. 2) Early treatment with clindamycin and pyrimethamine can be life-saving. 3) Serology is useful, but a negative titer does not rule out the disease in early stages. 4) Muscle biopsy with IHC is the gold standard for diagnosis. 5) In adult dogs, consider neosporosis in cases of unexplained myositis or polyradiculoneuritis. Pitfalls: 1) Delaying treatment while awaiting diagnostic tests can lead to irreversible damage. 2) Using corticosteroids alone without antiprotozoal therapy can worsen the infection. 3) Failing to consider neosporosis in adult dogs with immunosuppression. 4) Misinterpreting a positive serology as definitive diagnosis, as many dogs are subclinically infected. 5) Not monitoring for adverse effects of pyrimethamine, such as folate deficiency and bone marrow suppression.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Clindamycin: 10-20 mg/kg PO q8h for 4-8 weeks. May cause vomiting, diarrhea, and anorexia. 2) Pyrimethamine: 1 mg/kg PO q24h for 4-8 weeks. Can cause megaloblastic anemia, thrombocytopenia, and leukopenia; supplement with folinic acid (5 mg/day) to reduce toxicity. 3) Trimethoprim-sulfadiazine: 15-30 mg/kg PO q12h for 4-8 weeks. May cause keratoconjunctivitis sicca, hypersensitivity reactions, and bone marrow suppression. 4) In severe cases, a combination of clindamycin and trimethoprim-sulfadiazine may be used. 5) Corticosteroids (e.g., prednisone 0.5-1 mg/kg PO q12h) may be added for the first 1-2 weeks to reduce inflammation, but should be tapered quickly. 6) Supportive care: IV fluids (e.g., lactated Ringer's solution at maintenance rates), antiemetics (e.g., maropitant 1 mg/kg SC q24h) if vomiting, and nutritional support. 7) For aspiration pneumonia, use broad-spectrum antibiotics such as amoxicillin-clavulanate (12.5-25 mg/kg PO q12h) or enrofloxacin (5-10 mg/kg PO q24h). 8) Physical therapy: passive range-of-motion exercises and massage.

Key studies and consensus guidelines: 1) A study by Dubey et al. (2007) provides a comprehensive review of neosporosis in dogs, highlighting the clinical signs, diagnosis, and treatment. 2) A retrospective study by Barber and Trees (1996) reported that early treatment with clindamycin improved outcomes in puppies with neosporosis. 3) The ACVIM consensus statement on infectious diseases (2015) recommends clindamycin and pyrimethamine as first-line therapy for neosporosis. 4) A study by Peters et al. (2000) demonstrated the efficacy of trimethoprim-sulfadiazine in treating neosporosis. 5) A meta-analysis by Dubey and Schares (2011) summarized the global seroprevalence of N. caninum in dogs and cattle. 6) Recent research has focused on the development of vaccines for cattle, but no vaccine is available for dogs. 7) A study by Goodswen et al. (2013) identified potential vaccine candidates for N. caninum. 8) The use of PCR on CSF has been shown to be highly sensitive and specific for diagnosis (Peters et al., 2000). 9) A study by Lindsay et al. (1995) evaluated the efficacy of various antiprotozoal drugs against N. caninum in vitro, supporting the use of clindamycin and pyrimethamine. 10) Long-term follow-up studies indicate that dogs that survive the acute phase may have residual neurological deficits but can have a good quality of life with supportive care.